Dihydrexidine
http://dbpedia.org/resource/Dihydrexidine an entity of type: Thing
Dihydrexidine (DAR-0100) is a moderately selective full agonist at the dopamine D1 and D5 receptors. It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor. Although dihydrexidine has some affinity for the D2 receptor, it has functionally selective (highly biased) D2 signaling, thereby explaining why it lacks D2 agonist behavioral qualities. There have been several reviews of relevance to the compound.
rdf:langString
rdf:langString
Dihydrexidine
xsd:integer
3829067
xsd:integer
1051573529
rdf:langString
none
xsd:integer
17
xsd:integer
123039
xsd:integer
25856
xsd:integer
5036130
xsd:integer
17
xsd:integer
566
xsd:integer
1
xsd:integer
2
xsd:integer
5311070
rdf:langString
c1ccc2cCN[C@H]3[C@H]2c4ccO
xsd:integer
1
rdf:langString
BGOQGUHWXBGXJW-RHSMWYFYSA-N
xsd:integer
32
rdf:langString
changed
xsd:integer
414782444
rdf:langString
changed
rdf:langString
Dihydrexidine (DAR-0100) is a moderately selective full agonist at the dopamine D1 and D5 receptors. It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor. Although dihydrexidine has some affinity for the D2 receptor, it has functionally selective (highly biased) D2 signaling, thereby explaining why it lacks D2 agonist behavioral qualities. Dihydrexidine has shown impressive antiparkinson effects in the MPTP-primate model, and has been investigated for the treatment of Parkinson's disease. In an early clinical trial the drug was given intravenously and led to profound hypotension so development was halted. The drug was resurrected when it was shown that smaller subcutaneous doses were safe. This led to a pilot study in schizophrenia and current clinical trials to assess its efficacy in improving the cognitive and working memory deficits in schizophrenia and schizotypal disorder. There have been several reviews of relevance to the compound.
xsd:nonNegativeInteger
7098
xsd:string
123039-93-0
xsd:string
25856
xsd:string
32D64VH037
xsd:string
5311070